Oregovomab: Completed Phase II enrollment

Quest completed enrollment of 80 patients in an open-label, U.S. and Italian Phase IIb trial evaluating 2 mg IV oregovomab plus carboplatin and paclitaxel vs. carboplatin and paclitaxel. Oregovomab is...